SI9669: b-AP15

LifeSensors SI9669 is a specialized ubiquitin reagent designed for advanced research in protein regulation and ubiquitination pathways, supporting precise biochemical studies.

$80.00 – $377.00

SKU SI-9669 Categories DUB inhibitors, Proteasome Inhibitors, Small Molecule Modulators and PROTACs

Product Advantages

Applications

Validation studies of the deubiquitinating activities of the 19S regulatory particle as a drug target
Cell-based and in vitro characterization of UCH-L5 or USP14 activity
Inhibition of the 26S proteasome through a mechanism distinct from inhibition of 20S catalytic activity

Benefits

D’Arcy P. et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nature Medicine 2011 17:1636
D’Arcy P. and Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. Int. J. Biochem. Cell Biol. 2012 E Published ahead of print.

Blocks 26S proteasome activity by inhibiting the ubiquitin C-terminal hydrolase 5 (UCHL5) and ubiquitin-specific peptidase 14 (USP14) activities of the 19S regulatory subunit without affecting the catalytic activity of the 20S core subunit. b-AP15 displays several differences to bortezomib including insensitivity to over-expression of the anti-apoptotic mediator Bcl-2 and anti-tumor activity in four solid tumor models.

Info

Purity	>98% (TLC), NMR (conforms)
Quantity	5 mg, 25 mg
Molecular Weight	419.4 Da
Physical State	Pale yellow powder
Solubility	DMSO (35 mg/mL)
CAS No.	1009817-63-3
Storage	4°C, (-20°C Long term). The product can be shipped at room temperature.

Datasheet

Datasheet

Applications

Validation studies of the deubiquitinating activities of the 19S regulatory particle as a drug target
Cell-based and in vitro characterization of UCH-L5 or USP14 activity
Inhibition of the 26S proteasome through a mechanism distinct from inhibition of 20S catalytic activity

Benefits

D’Arcy P. et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nature Medicine 2011 17:1636
D’Arcy P. and Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. Int. J. Biochem. Cell Biol. 2012 E Published ahead of print.